#Switzerland #ADC Therapeutics #ZYNLONTA #Lausanne #Ameet Mallik

ADC Therapeutics at the 2026 Cantor Global Healthcare Conference

ADC Therapeutics SA, a leading innovator in antibody drug conjugates, has announced that its Chief Executive Officer, Ameet Mallik, will participate in a pivotal fireside chat at the 2026 Cantor Global Healthcare Conference. This event will take place on September 11, 2026, at 9:10 AM ET in New York City. This conference represents a significant opportunity not only for the company but also for the broader healthcare community to engage with ADC's mission and outlook.

During the fireside chat, Ameet Mallik is expected to share insights on the company's strategic direction, including advancements in their product portfolio and initiatives aimed at enhancing patient outcomes. ADC Therapeutics is currently at the forefront of developing innovative therapies, particularly with their flagship product, ZYNLONTA® (loncastuximab tesirine-lpyl), which has shown promise in the treatment of relapsed or refractory diffuse large B-cell lymphoma. This product has gained both accelerated approval from the FDA and conditional approval from the European Commission, highlighting ADC's commitment to transforming cancer treatment.

The webcast of the presentation will be available through the Investors section of ADC Therapeutics' website, providing a platform for stakeholders worldwide to participate. A replay is expected to be accessible for approximately 30 days following the event, ensuring widespread dissemination of the insights shared during the discussion.

Headquartered in Lausanne, Switzerland, ADC Therapeutics operates with a global perspective, focusing on antibody drug conjugates—a cutting-edge approach in oncology that combines the specificity of antibodies with the potent cell-killing abilities of cytotoxic drugs. This innovation could potentially change the treatment landscape for various cancers.

Alongside the presentation at the conference, ADC Therapeutics continues to advance its clinical programs, seeking new therapies and combinations to combat challenging oncological diseases. The company is poised to leverage its recent trial results, particularly from the LOTIS-5 clinical trial, which evaluates the efficacy of ZYNLONTA in a combination regimen.

Investors and industry experts will be watching closely as the company navigates the complexities of regulatory approvals and clinical development pathways that are crucial for maintaining its market position. Mallik's leadership, especially during this pivotal juncture, could shape the company's future trajectory.

For further updates and insights from the conference, be sure to visit adctherapeutics.com and follow ADC Therapeutics on social media platforms like LinkedIn. As the world looks toward innovative healthcare solutions, ADC Therapeutics aims to be at the forefront, driving change and delivering hope to patients and families affected by cancer.

In summary, the upcoming conference is a significant moment for ADC Therapeutics and its stakeholders. With Ameet Mallik at the helm of this discussion, many are eager to learn about the company's vision and how it plans to tackle the challenges facing the healthcare industry today. Stay tuned for more developments post-conference as ADC Therapeutics continues to pioneer advancements in cancer treatment.